I-MAB (IMAB) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. I-MAB's Revenue for the six months ended in Dec. 2023 was $1.12 Mil. I-MAB's average Accounts Receivable for the six months ended in Dec. 2023 was $0.00 Mil.

I-MAB Receivables Turnover Historical Data

The historical data trend for I-MAB's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Receivables Turnover Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

11.82

1.10

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial								2.12	2.94	-	-	-

Competitive Comparison of I-MAB's Receivables Turnover

For the Biotechnology subindustry, I-MAB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where I-MAB's Receivables Turnover falls into.

I-MAB Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

I-MAB's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	3.872	/ (	(0	+	0)	/	1 )
=	3.872	/	0
=	N/A

I-MAB's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	1.119	/ (	(0	+	0)	/	1 )
=	1.119	/	0
=	N/A

I-MAB (NAS:IMAB) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

I-MAB Receivables Turnover Related Terms

Thank you for viewing the detailed overview of I-MAB's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.